Egetis Therapeutics 관리

관리 기준 확인 2/4

Egetis Therapeutics CEO는 Nicklas Westerholm, Jun2017 에 임명되었습니다 의 임기는 7.42 년입니다. 는 € 118.14K 가치에 해당하는 회사 주식의 0.068% 직접 소유합니다. 118.14K. 경영진과 이사회의 평균 재임 기간은 각각 7.4 년과 6.4 년입니다.

주요 정보

Nicklas Westerholm

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.4yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	7.4yrs
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Nicklas Westerholm 의 보수는 Egetis Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 319m
Jun 30 2024	n/a	n/a	-SEK 319m
Mar 31 2024	n/a	n/a	-SEK 327m
Dec 31 2023	n/a	n/a	-SEK 327m
Sep 30 2023	n/a	n/a	-SEK 319m
Jun 30 2023	n/a	n/a	-SEK 286m
Mar 31 2023	n/a	n/a	-SEK 240m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 194m
Sep 30 2022	n/a	n/a	-SEK 148m
Jun 30 2022	n/a	n/a	-SEK 113m
Mar 31 2022	n/a	n/a	-SEK 114m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 104m
Sep 30 2021	n/a	n/a	-SEK 147m
Jun 30 2021	n/a	n/a	-SEK 153m
Mar 31 2021	n/a	n/a	-SEK 155m
Dec 31 2020	SEK 4m	SEK 2m	-SEK 178m
Sep 30 2020	n/a	n/a	-SEK 127m
Jun 30 2020	n/a	n/a	-SEK 134m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 61m
Sep 30 2019	n/a	n/a	-SEK 61m
Jun 30 2019	n/a	n/a	-SEK 48m
Mar 31 2019	n/a	n/a	-SEK 46m
Dec 31 2018	SEK 3m	SEK 2m	-SEK 85m
Sep 30 2018	n/a	n/a	-SEK 95m
Jun 30 2018	n/a	n/a	-SEK 103m
Mar 31 2018	n/a	n/a	-SEK 91m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 88m

보상 대 시장: German 시장에서 비슷한 규모의 회사에 비해 Nicklas 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: 회사가 수익성이 없는 동안 Nicklas 의 보상이 증가했습니다.

CEO

Nicklas Westerholm (48 yo)

7.4yrs

테뉴어

SEK 5,900,000

보상

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nicklas Westerholm	Chief Executive Officer	7.4yrs	SEK 5.90m	0.068% € 118.1k
Torsten Almén	Founder	18.8yrs	데이터 없음	데이터 없음
Ingemar Lundström	Founder	18.8yrs	데이터 없음	데이터 없음
Louis Ignarro	Founder	18.8yrs	데이터 없음	데이터 없음
Heidi Brurok	Founder	18.8yrs	데이터 없음	데이터 없음
Rob Towart	Founder	18.8yrs	데이터 없음	데이터 없음
Yilmaz Mahshid	Chief Financial Officer	3.4yrs	데이터 없음	0.087% € 152.4k
Katayoun Welin-Berger	Vice President of Operations	1.7yrs	데이터 없음	데이터 없음
Jacques Näsström	Chief Scientific Officer	no data	SEK 655.00k	데이터 없음
Karl Hard	VP and Head of Investor Relations & Communication	2.8yrs	데이터 없음	데이터 없음
Laetitia Szaller	General Counsel & Head of Compliance	less than a year	데이터 없음	데이터 없음
Peter Verwaijen	Global Head of Marketing & Brand Strategy	2.5yrs	데이터 없음	데이터 없음

7.4yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: P0F 의 관리팀은 노련하고 경험 (평균 재직 기간 7.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Dart	Member of Scientific Advisory Board	6.4yrs	데이터 없음	데이터 없음
Mats Blom	Chairman of the Board	3.6yrs	SEK 300.00k	0.87% € 1.5m
Behshad Sheldon	Independent Director	1.8yrs	데이터 없음	데이터 없음
Thomas Lonngren	Director	3.6yrs	SEK 600.00k	0.079% € 137.8k
Gunilla Osswald	Independent Director	7.8yrs	SEK 200.00k	0.011% € 19.5k
Elisabeth Svanberg	Independent Director	7.8yrs	SEK 200.00k	0.010% € 18.3k
Laura James	Member of Scientific Advisory Board	6.4yrs	데이터 없음	데이터 없음
James Dear	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.4yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: P0F 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

Egetis Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Director recently bought €85k worth of stock

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Recent updates

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.34 loss in 3Q 2023)

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

New minor risk - Shareholder dilution

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol

Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.32 loss in 2Q 2023)

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

First quarter 2024 earnings released: kr0.26 loss per share (vs kr0.31 loss in 1Q 2023)

Full year 2023 earnings released: kr1.27 loss per share (vs kr1.00 loss in FY 2022)

Full year 2023 earnings released: kr1.27 loss per share (vs kr1.00 loss in FY 2022)

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings released: kr0.34 loss per share (vs kr0.25 loss in 3Q 2022)

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.17 loss in 2Q 2022)

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Forecast breakeven date pushed back to 2025

Director recently bought €85k worth of stock

Egetis Terminates Discussions Regarding Potential Acquisition

Forecast to breakeven in 2024

First quarter 2023 earnings released: kr0.31 loss per share (vs kr0.17 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Forecast to breakeven in 2024

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.25 loss per share (vs kr0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.21 loss in 2Q 2021)

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Less than half of directors are independent

Full year 2021 earnings released: kr0.63 loss per share (vs kr2.64 loss in FY 2020)

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US

Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us

Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote

Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data

Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020)

Forecast to breakeven in 2023

Egetis Receives Approval in Turkey for Compassionate Use of Emcitate® for MCT8 Deficiency

Second quarter 2021 earnings released: kr0.21 loss per share (vs kr0.68 loss in 2Q 2020)

No longer forecast to breakeven

Insider recently bought €18k worth of stock

First quarter 2021 earnings released: kr0.12 loss per share (vs kr0.80 loss in 1Q 2020)

Full year 2020 earnings released: kr2.66 loss per share (vs kr1.19 loss in FY 2019)

Full year 2020 earnings released: kr2.66 loss per share (vs kr1.19 loss in FY 2019)

Revenue beats expectations

Egetis Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Mar 30, 2021

Egetis Therapeutics AB (Publ) Appoints Dr. Kristina Sjöblom Nygren as New Cmo, Effective May 1, 2021

Egetis Therapeutics Announces Executive Changes

New 90-day high: €0.87

New 90-day high: €0.72

Pledpharma AB and Solasia Pharma K.K. Announce Results from the Prematurely Closed Pledox®(Sp-04) Polar Program

New 90-day high: €0.66

PledPharma to Be Deleted from Other OTC